Amwill Health Care Ltd (544353)
சுருக்கம்
நிகழ்வுகள்
- சமீபத்திய முடிவுகள்
- H1 FY27, filed 23 Oct 2026
- கடைசி எக்ஸ்-டிவிடெண்ட்
- ஒரு பங்குக்கு ₹0.50, 30 அக். 2026 அன்று
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
H1 FY27 முடிவுகள்
Amwill Health Care Ltd reported H1 FY27 results on 23 Oct 2026: revenue ₹22.6 Cr (+7.8% year on year, -5.7% on the previous half-year), and net profit ₹3.7 Cr (-8.2% year on year); the operating margin was 15.2%.
| H1 FY27 (₹ கோடி) | மதிப்பு | YoY H1 FY26-உடன் | முந்தைய அரையாண்டுடன் ஒப்பீடு |
|---|---|---|---|
| வருவாய் | ₹22.6 | +7.8% | -5.7% |
| செயல்பாட்டு லாபம் | ₹3.4 | -13.9% | -61.7% |
| நிகர லாபம் | ₹3.7 | -8.2% | -54.1% |
| EPS (₹) | 1.84 | -4.7% | -51.2% |
| செயல்பாட்டு லாப வரம்பு | 15.2% | — | — |
- லாபம் அதன் சொந்தப் போக்கை விட -29% கீழே
- செயல்பாட்டு லாப வரம்பு 382 bps YoY குறைந்தது
- வரிக்கு முந்தைய லாபத்தில் 38% மற்ற வருமானம் மற்றும் ஒருமுறை கிடைத்த வருமானங்களிலிருந்து வந்தது.
லாபத்தின் தரம்: வரிக்கு முந்தைய ₹5.2 கோடி லாபத்தில், ₹3.2 கோடி (62%) முக்கிய வணிகத்திலிருந்து வந்தது; மீதம் பிற வருமானம் மற்றும் ஒருமுறை வரவுகளிலிருந்து வந்தது. முக்கிய லாபம் (செயல்பாட்டு லாபத்தில் வட்டி மற்றும் தேய்மானத்தைக் கழித்தது) YoY அடிப்படையில் -20.0% மாறியுள்ளது.
அதன் சொந்தப் போக்குக்கு எதிராக: நிகர லாபம் ₹3.7 கோடியாக இருந்தது; இது, அதன் சமீபத்திய வளர்ச்சி சுட்டிக்காட்டிய ₹5.1 கோடியுடன் ஒப்பிடும்போது -28.6% ஆகும் (below trend). இது ஒரு புள்ளியியல் அடிப்படை மட்டுமே; ஆய்வாளர் மதிப்பீடு அல்ல.
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
Amwill Health Care Ltd has committed ₹3.00 crore to Nippon India Credit Opportunities AIF Scheme II, a SEBI-registered Alternative Investment Fund. This deployment is funded entirely through internal accruals and will be drawn down in tranches, following an investment limit approved on August 08, 2026. The commitment represents approximately 3.7% of the company's net worth of ₹81 crore and 3.5% of its TTM revenue of ₹85 crore. The AIF, its sponsor, and manager are confirmed as non-related parties.
- Committed ₹3,00,00,000/- (Rupees Three Crore only) to Nippon India Credit Opportunities AIF Scheme II
- Commitment represents ~3.7% of net worth (₹81 Cr) and ~3.5% of TTM revenue (₹85 Cr)
- Funded through internal accruals and will be drawn down in multiple tranches
- AIF, sponsor, and manager are not related parties of the company
Amwill Health Care Ltd announced an interim dividend of ₹0.50 per equity share (5% on face value of ₹10) for FY 2026-27. The company's board fixed October 30, 2026, as the record date to determine eligible shareholders. The dividend payout will be completed within 30 days from the declaration date. The board also approved the unaudited financial results for the half year ended September 30, 2026.
- Interim dividend declared at ₹0.50 per equity share of face value ₹10 each
- Dividend rate represents 5% of paid-up share capital value
- Record date fixed as October 30, 2026
- Dividend disbursement to be completed within 30 days of declaration
Amwill Health Care has secured a new regulatory licence from the Central Drugs Standard Control Organization (CDSCO) to import FoliColor- Oxidative hair colour (Black variant) into India. The registration certificate (RC/COS- 007631) is valid for five years from October 8, 2026, to October 7, 2031. This approval allows the company to commence import and commercial sales in India, adding to its product portfolio against a backdrop of TTM revenue of ₹85 crore. The counterparty or supplier is confirmed as a non-related party.
- CDSCO granted import registration certificate No. RC/COS- 007631 for FoliColor hair colour (Black variant)
- Licence valid for 5 years from October 8, 2026, upto October 7, 2031
- Approval received by the company on October 9, 2026
- Enables commercial import and retail sale in India with an unrelated party supplier
Amwill Health Care Limited's Investment Committee has approved investments totaling up to ₹3.00 crore across two Alternative Investment Funds (AIFs) from internal accruals. The company will invest up to ₹1.50 crore in units of Vivriti Vihaan Trust and up to ₹1.50 crore in Neo Income Plus Fund III. The total investment of ₹3 crore represents approximately 3.5% of the company's TTM revenue of ₹85 crore and 3.7% of its net worth of ₹81 crore. The transaction does not involve any related parties and is scheduled to be deployed in the ensuing months.
- Approval to invest up to INR 1,50,00,000 in Vivriti Vihaan Trust (SEBI-registered AIF)
- Approval to invest up to INR 1,50,00,000 in Neo Income Plus Fund III (Neo Credit Alternatives Investment Trust)
- Total investment of up to ₹3.00 crore to be funded fully via internal accruals
- Confirmed zero related-party involvement in the investment transactions
Amwill Health Care Limited announced that its shareholders at the 9th Annual General Meeting approved the re-appointment of Mr. Tarun Gandhi and Mr. Anand Gandhi as Managing Directors. The re-appointments are for a period of 5 consecutive years commencing January 27, 2027, through January 26, 2032. Both executives possess over a decade of experience across financial management and dermatology brand marketing. The decision ensures leadership continuity for the company, which reported TTM revenue of Rs 85 Cr and TTM PAT of Rs 23 Cr.
- Shareholders approved 5-year re-appointment of Managing Directors at the 9th AGM on August 14, 2026
- Term for Mr. Tarun Gandhi (DIN: 07854699) runs from January 27, 2027 to January 26, 2032
- Term for Mr. Anand Gandhi (DIN: 07854706) runs from January 27, 2027 to January 26, 2032
- Both directors are Key Managerial Personnel and not liable to retire by rotation
Amwill Health Care has approved a new hybrid treasury strategy to deploy surplus cash from internal accruals into a multi-asset framework. The company has set aggregate limits totaling ₹33 crore across various asset classes, including debt, equity, and alternative investments. This total limit represents approximately 40.7% of the company's current net worth of ₹81 crore. The strategy aims to optimize post-tax, risk-adjusted returns while maintaining a base in traditional fixed deposits.
- Total investment limit of ₹33 crore approved across five distinct financial segments using internal accruals
- Allocation of up to ₹15 crore (18.5% of Net Worth) for Private Credit Funds, AIFs, and Structured Debt
- Limit of ₹2 crore set for investments in listed equity shares and both Mainboard and SME IPOs
- Debt instruments including G-Secs, NCDs, and Commercial Papers capped at an aggregate of ₹10 crore
- Additional ₹3 crore limits each for Mutual Fund SIPs and invoice discounting platforms
Amwill Health Care has approved the re-appointment of Mr. Tarun Gandhi and Mr. Anand Gandhi as Managing Directors for a five-year term commencing January 27, 2027. The company, which operates with a TTM revenue of ₹85 Cr and a healthy 29.4% operating margin, is seeking shareholder approval for these roles at its 9th AGM on August 14, 2026. The leadership continuity is significant for a debt-free firm with a net worth of ₹81 Cr and a high ROCE of 21.0%. The record date for voting eligibility is set for August 8, 2026.
- Re-appointment of two Managing Directors for a 5-year tenure from January 27, 2027, to January 26, 2032
- 9th Annual General Meeting (AGM) scheduled for August 14, 2026, via video conferencing
- Record date for determining shareholder voting rights fixed as August 8, 2026
- Company maintains a debt-free balance sheet with ₹0 Cr debt and ₹81 Cr net worth
- TTM PAT stands at ₹23 Cr on a revenue base of ₹85 Cr
Amwill Health Care's Investment Committee has approved placing ₹2 crores into a Fixed Deposit (FD) with Vysya Co-operative Bank (Tumkur), Bangalore. The investment is funded entirely through the company's internal accruals and is intended to support its long-term growth strategy. Given the company's net worth of ₹81 crore and zero debt status, this represents a small treasury allocation of approximately 2.5% of its net worth. The company confirmed that this is not a related-party transaction.
- Investment Committee approved a Fixed Deposit of ₹2 Crores on July 23, 2026
- Funds are sourced from internal accruals, maintaining the company's zero-debt status
- Deposit will be placed with Vysya Co-operative Bank (Tumkur), Bangalore branch
- Investment represents approximately 2.47% of the company's ₹81 Crore net worth
Amwill Health Care has scheduled its 9th Annual General Meeting (AGM) for August 14, 2026, to approve a final dividend of ₹0.50 per share for FY 2025-26. A key agenda item is the re-appointment of two Managing Directors, Mr. Tarun Gandhi and Mr. Anand Gandhi, for five-year terms starting January 2027. Each MD is proposed to receive a basic salary of up to ₹1.572 Cr per annum, totaling ₹3.144 Cr for both. This combined maximum remuneration represents approximately 13.6% of the company's TTM PAT of ₹23 Cr.
- Proposed final dividend of ₹0.50 per equity share of ₹10 face value for FY 2025-26
- Re-appointment of two Managing Directors for 5-year terms (2027-2032) with a maximum salary of ₹1.572 Cr each per annum
- Combined maximum MD remuneration of ₹3.144 Cr accounts for ~3.7% of TTM Revenue (₹85 Cr)
- Cut-off date for dividend and voting eligibility fixed for August 08, 2026
- AGM to be held via Video Conferencing on August 14, 2026
Amwill Health Care has fixed August 08, 2026, as the record date for its final dividend for FY 2025-26 and for determining shareholder eligibility for its 9th Annual General Meeting (AGM). The Board has approved the re-appointment of Managing Directors Mr. Tarun Gandhi and Mr. Anand Gandhi for a five-year term effective from January 27, 2027. The 9th AGM is scheduled for August 14, 2026, via video conferencing. Remote e-voting for shareholders will be available from August 11 to August 13, 2026.
- Record date for final dividend and AGM voting eligibility fixed for August 08, 2026
- Re-appointment of two Managing Directors for a 5-year term from January 27, 2027, to January 26, 2032
- 9th Annual General Meeting scheduled for August 14, 2026, at 01:00 PM IST
- Remote e-voting period set from August 11, 2026 (09:00 AM) to August 13, 2026 (05:00 PM)
- Approval of the Annual Report for the financial year 2025-26
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
